In August–September 2025, Surgerii Robotics recorded two milestones within weeks of each other: SHURUI, its single-port surgical robot, received CE certification under the EU Medical Device Regulation, and the company closed a $100 million Series D led by Loyal Valley Capital. Together the two events mark Surgerii’s shift from domestic approval holder to a company with a funded plan for international commercialization.
What CE Under EU MDR Actually Requires
The EU MDR — Regulation (EU) 2017/745 — replaced the older Medical Device Directive with a substantially more demanding conformity assessment framework. For Class III devices, which include surgical robots, the regulation requires clinical evaluation based on clinical data generated from the device itself, not analogous products. Notified bodies must conduct full quality management system audits and technical documentation reviews. Post-market clinical follow-up plans and periodic safety update reports become mandatory obligations after certification.
Most Chinese medical device companies that have pursued European market access in recent years obtained CE marks under the older MDD before it expired for new devices in May 2024. Certifications issued after that transition point are by definition issued under the more rigorous EU MDR framework. According to Surgerii’s announcement, SHURUI’s CE certification was issued under EU MDR, covering use in urology, gynecology, general surgery, and thoracic surgery across adult and pediatric patients.
The pediatric coverage point is one Surgerii has highlighted: according to the company, SHURUI is described as the first domestically developed single-port surgical robot to receive EU MDR certification with pediatric indications included. Pediatric minimally invasive surgery imposes tighter tolerances on instrument sizing and maneuverability — a smaller working space requires instruments that can articulate without fouling each other. The SHURUI snake-arm architecture, described further below, is relevant to this constraint.
The Snake-Arm Architecture
SHURUI’s design is built around what Surgerii calls a hyper-redundant continuum arm — a flexible, multi-segment manipulator that moves along a curved path rather than rotating around fixed pivot joints. The single-port approach inserts multiple such arms through a single small incision, typically at the umbilicus, rather than the three to five separate port sites used in conventional multi-port laparoscopic procedures.
Surgerii has described the core engineering challenge as triangulation: in multi-port surgery, separate incision sites create natural triangulation between instruments and target tissue. In single-port surgery, all instruments must enter from the same axis, then re-triangulate inside the body. The snake-arm configuration achieves this by allowing each instrument to curve away from the insertion axis after passing through the port — creating working angles that conventional rigid instruments cannot achieve through a single incision.
The system supports simultaneous insertion of a 3D endoscope and multiple surgical instruments through the single port. Surgerii holds a substantial domestic patent portfolio in continuum arm mechanics and control, developed over the company’s eleven years of operation since its 2014 founding in Beijing.
The clinical relevance for the four approved specialties — urology, gynecology, general surgery, thoracic surgery — is that all involve procedures in confined body cavities where post-incision angulation capability is directly tied to what maneuvers are achievable. Thoracic surgery in particular, where the chest wall limits access angles, benefits from instruments that can work in orientations a rigid port cannot approach.
The Competitive Context: Da Vinci SP
The direct reference point for single-port surgical robotics internationally is Intuitive Surgical’s da Vinci SP, which received FDA clearance in 2018 for urological procedures and has since expanded its approved indications. The da Vinci SP uses a different mechanical approach — a single large-bore port that contains a camera and three fully wristed instruments — but addresses the same clinical objective as SHURUI.
Intuitive held CE certification for the da Vinci SP under the older MDD; as of the SHURUI announcement, Intuitive’s European single-port certification status under the current EU MDR framework had not been publicly confirmed by Intuitive. Surgerii’s communications have positioned SHURUI as CE MDR-certified for a broader specialty coverage than publicly announced CE single-port competitors, though independent comparative analysis of European certification status across all platforms has not been verified.
The da Vinci SP carries a list price well above the mid-range of capital equipment budgets at European hospitals. Chinese surgical robot manufacturers have generally been able to offer lower capital acquisition costs in markets where they compete — a dynamic that VCBeat Health’s 2026 analysis cited as contributing to Chinese overseas order volumes growing faster than the overall global installed base for surgical robots.
The Series D: Syndicate and Use of Proceeds
According to MedTech Dive, the $100 million Series D was led by Loyal Valley Capital, a Chinese growth-stage investor with a healthcare and technology portfolio. The publication reported the round closed in September 2025, shortly after the CE mark announcement.
Surgerii disclosed that proceeds will fund global commercialization, which encompasses building out international sales infrastructure, regulatory submissions in additional markets beyond Europe, and clinical program development. At $100 million, the round is among the larger funding events in Chinese medical robotics in 2025, though it falls below Cornerstone Robotics’ approximately $270 million raised across two 2025 rounds.
The timing of the CE mark and the funding close within weeks of each other reflects a funding dynamic that has appeared in other Chinese medical device internationalization sequences: CE certification under a recognized notified body substantially strengthens the prospectus for international commercialization investment by validating that the device meets regulatory standards in the world’s second-largest medical device market.
Surgerii’s prior rounds included Series C1 and C3 tranches described as “hundreds of millions of RMB,” plus an undisclosed Series B+ round. The Series D brings total disclosed funding to a level consistent with a company preparing for a possible IPO in subsequent years, following a trajectory similar to Edge Medical and other Chinese surgical robot makers that used Hong Kong listings to access international institutional capital.
Indications Breadth as Differentiation
Most single-port robotic platforms initially received regulatory clearance for a single specialty and expanded indications over time. SHURUI’s CE certification covering four specialties from initial issuance — including both the conventional urology and gynecology applications and the more demanding thoracic surgery indication — expands the addressable case volume in European hospitals from day one of commercialization.
Thoracic surgery robotic procedures in Europe have historically been performed with multi-port systems including Intuitive’s multi-arm da Vinci Xi. A single-port robot with certified thoracic coverage enters a specialty where the procedural volume is meaningful and single-port access would address the intercostal incision burden that limits adoption of conventional multi-port thoracic robotics.
The pediatric indication, as described by Surgerii, represents a further differentiation: pediatric minimally invasive surgery is performed in lower volumes than adult surgery, but the technical requirements create a certification gate that not all platforms have cleared. Surgerii describes SHURUI as the first domestically developed single-port robot to carry this certification, though verification against all EU MDR-certified single-port platforms globally was not independently confirmed.
What Comes Next
With CE certification in hand and $100 million in committed capital, Surgerii’s near-term execution focus is building commercial traction in Europe and preparing submissions in additional regulated markets. The NMPA had already approved SHURUI for domestic use, giving the company a domestic clinical base from which to generate post-market data relevant to other regulatory submissions.
The company has not announced a timeline for FDA submission as of the Series D close, though US market access for surgical robots requires a 510(k) clearance or de novo pathway — a separate regulatory process from the EU MDR track. Several Chinese surgical robot makers have indicated US submissions as medium-term targets; Surgerii has not publicly disclosed its US regulatory timeline.
The combination of EU MDR certification, pediatric indication coverage, and funded international infrastructure places Surgerii among the Chinese single-port platforms with the most structured path to international commercial deployments in 2026. See the Surgical Robots hub for a category overview of robotically-assisted surgical platforms approved in China.